Reported Saturday, Natera's Signatera Predicts Overall Survival In Colorectal Cancer, New Data From GALAXY Study Released At ESMO
Portfolio Pulse from Benzinga Newsdesk
Natera's Signatera test shows significant predictive power for overall survival in colorectal cancer patients, according to new data from the GALAXY study presented at ESMO. The test indicates a nearly 10x advantage in survival at 36 months based on ctDNA status and a 50% reduction in death risk for Signatera-positive patients treated with ACT.
September 16, 2024 | 7:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Natera's Signatera test demonstrates a significant predictive advantage in colorectal cancer survival, potentially boosting the company's market position and stock price.
The new data from the GALAXY study presented at ESMO highlights the effectiveness of Natera's Signatera test in predicting overall survival in colorectal cancer patients. This could enhance Natera's reputation and demand for its products, likely leading to a positive impact on its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100